Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | VEGFA | P15692 | 3/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200385 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL9230804 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL13561243 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL7049923 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL21662370 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL9231092 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL9229342 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL8506716 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL12427213 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM | |
| SCHEMBL2195712 | 1.00 | TLR4 (0.53) | TLR4SLC2A1DGKAAKT1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4121060-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | Board of Regents, The University of Texas System (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188586-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-2663314-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | The University of Texas M.D. Anderson Cancer (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012097052-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20050196342-A1 | Contrast agents | GE HEALTHCARE AS (NO) | 2005-09-08 | — | — | US | disclosed |
| US-20050031543-A1 | Microbubble-generating carbohydrate microparticles with an incorporated surfactant for enhanced echocardiographic imaging | AMERSHAM HEALTH AS | 2005-02-10 | — | — | US | disclosed |
| US-20030059373-A1 | Contrast agents | NYCOMED IMAGING AS | 2003-03-27 | — | — | US | disclosed |
| EP-0620744-B1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-04-12 | — | — | EP | disclosed |
| EP-0972527-A2 | Contrast agents containing carbohydrate particles and a surfactant | NYCOMED IMAGING AS (NO) | 2000-01-19 | — | — | EP | disclosed |
| US-5827502-A | COMPRISING A CARBOHYDRATE MIXED WITH A SURFACTANT AND A BIOCOMPATIBLE LOW-MOLECULAR-WEIGHT FLUORINATED HYDROCARBON AS GAS; DIAGNOSTIC ULTRASONIC AND MAGNETIC RESONANCE IMAGING | NYCOMED IMAGING AS (NO) | 1998-10-27 | — | — | US | disclosed |
| EP-0586524-B1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1997-04-23 | — | — | EP | disclosed |
| US-5569449-A | BIOTOLERABLE MATRIX IN ASSOCIATION WITH FLUORINATED GAS, STABILIZED BY PRESENCE OF CROSS-LINKING GROUPS ATTACHED TO MATRIX | NYCOMED IMAGING AS (NO) | 1996-10-29 | — | — | US | disclosed |
| US-5558857-A | ULTRASONIC | NYCOMED IMAGING AS (NO) | 1996-09-24 | — | — | US | disclosed |
| EP-0620744-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1994-10-26 | — | — | EP | disclosed |
| EP-0586524-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS. | HOLMES MICHAEL JOHN (GB) | 1994-03-16 | — | — | EP | disclosed |
| WO-1993013808-A2 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | HOLMES, MICHAEL, JOHN (GB) | 1993-07-22 | — | — | WO | disclosed |
| WO-1992021382-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | HOLMES, MICHAEL, JOHN (GB) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | G6PD, FBP1, ALDOA | TLR4 658/4885SLC2A1 9/4885DGKA 3642/4885 |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | IGF1R, IRS1, IGFBP1 | TLR4 454/4885SLC2A1 21/4885DGKA 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.